Literature DB >> 15644865

Antimony-induced cardiomyopathy in guinea-pig and protection by L-carnitine.

Marco Alvarez1, Claire O Malécot, François Gannier, Jacques M Lignon.   

Abstract

Antimony (Sb) is the mainstay for the treatment of Leishmaniasis. It has serious, often lethal, cardiovascular side effects. The objective of this study was to examine the effects of Sb treatment upon the electrocardiogram (ECG), myocyte contractility (assessed by monitoring sarcomere length during field stimulation), whole-cell action potential (AP) and calcium current (I(Ca)) of the guinea-pig and to evaluate L-carnitine as a cardioprotective agent. Guinea-pigs received daily injections of either saline, Sb(V), Sb(III), L-carnitine or L-carnitine with Sb(III). Eight lead ECGs were recorded under halothane anaesthesia every 4 days. At the end of each treatment regime, animals were killed and ventricular myocytes were enzymatically isolated. Treatment with Sb(V) for 26 days prolonged the QT interval of the ECG. Treatment with Sb(III) was lethal within 2 days for approximately 50% of the animals. The survivors showed ECG alterations similar to those described in man: T wave flattening and/or inversion, depression of the ST segment, and elongation of RR and QT intervals. Their ventricular myocytes showed impaired contraction responses to changes in stimulus frequency, elongated AP and reduced I(Ca). Combined treatment with L-carnitine and Sb(III) delayed mortality. Prior treatment with L-carnitine followed by combined treatment with L-carnitine and Sb(III) reduced mortality to <10% over 12 days and these animals showed normal ECG. Their myocytes showed normal contractility and AP. It is concluded that L-carnitine has a preventive cardioprotective role against antimony-induced cardiomyopathy. The mechanism of action of L-carnitine may be to counter oxidative stress caused by Sb(III).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15644865      PMCID: PMC1575978          DOI: 10.1038/sj.bjp.0706030

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  49 in total

1.  Calmodulin binding and inhibition of cardiac muscle calcium release channel (ryanodine receptor).

Authors:  D M Balshaw; L Xu; N Yamaguchi; D A Pasek; G Meissner
Journal:  J Biol Chem       Date:  2001-03-27       Impact factor: 5.157

Review 2.  Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review.

Authors:  E L De Beer; A E Bottone; E E Voest
Journal:  Eur J Pharmacol       Date:  2001-03-09       Impact factor: 4.432

Review 3.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 4.  Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass.

Authors:  R Lango; R T Smolenski; M Narkiewicz; J Suchorzewska; W Lysiak-Szydlowska
Journal:  Cardiovasc Res       Date:  2001-07       Impact factor: 10.787

5.  Interaction of antimony tartrate with the tripeptide glutathione implication for its mode of action.

Authors:  H Sun; S C Yan; W S Cheng
Journal:  Eur J Biochem       Date:  2000-09

6.  L-carnitine prevents increase in diastolic [CA2+] induced by doxorubicin in cardiac cells.

Authors:  A Mijares; J R López
Journal:  Eur J Pharmacol       Date:  2001-08-10       Impact factor: 4.432

7.  Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani.

Authors:  P Shaked-Mishan; N Ulrich; M Ephros; D Zilberstein
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

8.  Differences in Ca(2+)-handling and sarcoplasmic reticulum Ca(2+)-content in isolated rat and rabbit myocardium.

Authors:  L S Maier; D M Bers; B Pieske
Journal:  J Mol Cell Cardiol       Date:  2000-12       Impact factor: 5.000

9.  Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate.

Authors:  F Frézard; C Demicheli; C S Ferreira; M A Costa
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

10.  In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.

Authors:  W L Roberts; J D Berman; P M Rainey
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

View more
  6 in total

1.  Contribution of environmental toxins in the pathogenesis of idiopathic cardiomyopathies.

Authors:  Antonio L Perez; W H Wilson Tang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-05

Review 2.  Environmental Metals and Cardiovascular Disease in Adults: A Systematic Review Beyond Lead and Cadmium.

Authors:  Anne E Nigra; Adrian Ruiz-Hernandez; Josep Redon; Ana Navas-Acien; Maria Tellez-Plaza
Journal:  Curr Environ Health Rep       Date:  2016-12

Review 3.  Mechanisms underlying the anti-wasting effect of L-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies.

Authors:  Robert Ringseis; Janine Keller; Klaus Eder
Journal:  Eur J Nutr       Date:  2013-03-19       Impact factor: 5.614

4.  Electrocardiogram abnormalities in antimony exposed workers in the automotive brake lining manufacturing industry: a case report.

Authors:  Ha-Ram Jo; Seongyong Yoon; Jinseok Kim; Seong-Yong Cho; Jong-Min An; Gayoung Kim
Journal:  Ann Occup Environ Med       Date:  2022-06-27

5.  Plasma level of antimony correlates with pulmonary arterial hypertension severity.

Authors:  Karim El-Kersh; C Danielle Hopkins; Xiaoyong Wu; Shesh N Rai; Lu Cai; Jiapeng Huang
Journal:  Curr Res Toxicol       Date:  2022-06-27

6.  Concurrent Heavy Metal Exposures and Idiopathic Dilated Cardiomyopathy: A Case-Control Study from the Katanga Mining Area of the Democratic Republic of Congo.

Authors:  Didier Malamba-Lez; Désire Tshala-Katumbay; Virginie Bito; Jean-Michel Rigo; Richie Kipenge Kyandabike; Eric Ngoy Yolola; Philippe Katchunga; Béatrice Koba-Bora; Dophra Ngoy-Nkulu
Journal:  Int J Environ Res Public Health       Date:  2021-05-06       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.